| 0.7115 -0.012 (-1.6%) | 01-26 13:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.9 | 1-year : | 0.99 |
| Resists | First : | 0.77 | Second : | 0.85 |
| Pivot price | 0.71  |
|||
| Supports | First : | 0.65 | Second : | 0.54 |
| MAs | MA(5) : | 0.72  |
MA(20) : | 0.72 |
| MA(100) : | 1.19 |
MA(250) : | 3.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 40.3 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 7.28 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATYR ] has closed above bottom band by 45.6%. Bollinger Bands are 94.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.75 |
| Low: | 0.71 - 0.71 | 0.71 - 0.71 |
| Close: | 0.72 - 0.72 | 0.72 - 0.73 |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Mon, 19 Jan 2026
aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest - MarketBeat
Sun, 11 Jan 2026
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Thu, 08 Jan 2026
aTyr Pharma (NASDAQ:ATYR) Stock Price Up 3.1% - Still a Buy? - MarketBeat
Mon, 15 Dec 2025
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - PR Newswire
Thu, 06 Nov 2025
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update - Yahoo Finance
Fri, 10 Oct 2025
aTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial Failure - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 9.554e+007 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 29,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.798e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 76.3 % |
| Return on Equity (ttm) | -49.6 % |
| Qtrly Rev. Growth | 190000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -169.66 |
| EBITDA (p.s.) | -1.00607e+008 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.53 |
| Dividend | 0 |
| Forward Dividend | 2.501e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|